
Main Responsibilities of the National Medical Products Administration (1) To supervise the safety of drugs (including traditional Chinese medicines (TCMs) and ethno-medicines, the same below), medical devices and cosmetics; to draw up regulatory policy plans, organize the drafting of laws and regulations, formulate normative documents, and supervise the implementation thereof; to research and formulate regulatory and supportive policies that encourage new technologies and new products for drugs, medical devices and cosmetics. (2) To undertake standards management for drugs, medical devices and cosmetics; to organize the formulation and publication of the Chinese Pharmacopoeia and other drug and medical device standards, organize the drafting of cosmetic standards, organize the formulation of the classification management system, and supervise the implementation thereof; to participate in formulating the National Essential Medicine List, and assist in the implementation of the national essential medicine system. (3) To regulate the registration of drugs, medical devices and cosmetics; to develop the registration system, conduct strict review and approval for marketing, improve measures to facilitate the review and approval process, and organize the implementation thereof. (4) To undertake quality management for drugs, medical devices and cosmetics; to develop Good Laboratory Practices (GLP) and Good Clinical Practices (GCP), and supervise the implementation thereof; to develop Good Manufacturing Practices (GMP) and supervise the implementation thereof in line with NMPA's responsibilities; to develop good practices on the distribution and use of medical products and guide the implementation thereof.
Unlock the market timeline & signal feed
New Partnerships activity — 3 fresh signals just appeared.
The order this company entered each market — oldest to newest
Antengene Receives CDE Endorsement for ATG-022 Phase III
Kelun-Biotech Receives IND Approval for SKB118
Sign up to see the full signal feed
How NMPA-National Medical Products Administration's international expansion compares to its competitors
Bars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
NMPA-National Medical Products AdministrationYou | 4 | 2 | +300% | 5 | 19 |
Not hiring right now
Sign up to track this company and get alerted the moment something changes.
No tracked technology yet
Sign up to track this company and get alerted the moment something changes.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
Chance Pharmaceuticals announced China's NMPA accepted its NDA for CXG87, an innovative budesonide/formoterol inhalation powder for asthma treatment, marking the company's first NDA submission and commercialization milestone.
Otsuka Pharmaceutical announced NMPA approval of sibeprenlimab (Voyxact), the first biologic for IgA nephropathy, based on Phase 3 VISIONARY trial showing 51.2% proteinuria reduction at 9 months in adults with disease progression risk.
Hengrui Pharma announced Phase III CARES-336 trial results at ASCO 2026, showing camrelizumab plus rivoceranib with TACE significantly improved PFS versus TACE alone in unresectable hepatocellular carcinoma patients.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about NMPA-National Medical Products Administration's business, markets, and growth signals.

© 2026 Pubrio. All rights reserved.